BioSpace News Archive

Incyte announced the full 24-week results from its pivotal Phase 3 TRuE-V clinical trial program investigating ruxolitinib cream, a topical JAK inhibitor, in adolescent and adult patients with nonsegmental vitiligo.

AnaptysBio, Inc., a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, announced that week 16 data from the GPP GALLOP Phase 2 trial of imsidolimab, its investigational anti-interleukin-36 receptor therapeutic antibody, was presented at the 2021 European Academy of Dermatology and Venereology Congress.

Amgen and Kyowa Kirin Co., Ltd. announced that positive data from a Phase 2 study of AMG 451/KHK4083 were presented at the European Academy of Dermatology and Venereology 30th Virtual Congress on Oct. 2, 2021.

Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, is presenting new data from three studies demonstrating the potential clinical utility of T-cell testing using T-cell receptor repertoire characterization for infectious diseases during IDWeek 2021, which is being held virtually.

AbbVie announced new data on the investigational use of risankizumab in Crohn’s disease, upadacitinib in ulcerative colitis and HUMIRA® in inflammatory bowel disease will be presented as live presentations and e-Posters at the United European Gastroenterology Week Virtual 2021, to be held October 3-5.

Seres Therapeutics, Inc., a leading microbiome therapeutics company, announced late-breaking data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapeutic for recurrent C. difficile infection.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that its investigational respiratory syncytial virus vaccine candidate was highly effective in protecting against lower respiratory tract disease caused by RSV, demonstrating vaccine efficacy of 80 percent in adults aged 65 and older.